Madrigal Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-465.89	-373.63	-295.35	-241.85	-202.24	Upgrade
Depreciation & Amortization	1.1	0.53	0.47	0.41	0.47	Upgrade
Other Amortization	2.09	2.41	0.8	-	-	Upgrade
Stock-Based Compensation	79.88	49.74	31.63	26.87	20.73	Upgrade
Other Operating Activities	-0.4	-	-	-	-	Upgrade
Change in Accounts Receivable	-53.82	-	-	-	-	Upgrade
Change in Inventory	-34.07	-	-	-	-	Upgrade
Change in Accounts Payable	15.56	4.21	2.45	20.36	-0.16	Upgrade
Change in Other Net Operating Assets	-0.01	-7.49	35.15	10.29	23.64	Upgrade
Operating Cash Flow	-455.57	-324.23	-224.86	-183.92	-157.56	Upgrade
Capital Expenditures	-1.46	-1.48	-0.22	-0.21	-0.33	Upgrade
Sale (Purchase) of Intangibles	-5	-	-	-	-	Upgrade
Investment in Securities	-267.92	-501.04	206.9	-4.85	160.11	Upgrade
Investing Cash Flow	-274.39	-502.52	206.69	-5.06	159.78	Upgrade
Long-Term Debt Issued	-	65	50	-	-	Upgrade
Total Debt Issued	-	65	50	-	-	Upgrade
Net Debt Issued (Repaid)	-	65	50	-	-	Upgrade
Issuance of Common Stock	735.06	530.48	264.34	171.24	5.09	Upgrade
Other Financing Activities	-	-0.36	-0.89	-	-	Upgrade
Financing Cash Flow	735.06	595.12	313.45	171.24	5.09	Upgrade
Net Cash Flow	5.1	-231.63	295.28	-17.74	7.31	Upgrade
Free Cash Flow	-457.03	-325.71	-225.07	-184.13	-157.9	Upgrade
Free Cash Flow Margin	-253.72%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-21.48	-17.43	-13.13	-11.13	-10.22	Upgrade
Levered Free Cash Flow	-296.99	-192.38	-115.68	-94.62	-86.74	Upgrade
Unlevered Free Cash Flow	-289.91	-186.85	-114	-94.62	-86.74	Upgrade
Change in Net Working Capital	53.25	-2.17	-37.61	-29.87	-21.56	Upgrade

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q